abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기사

2006년 9월 25일

저자:
Kaiser Network Daily HIV/AIDS Report [USA]

Roche To Transfer Technology for Protease Inhibitor Saquinavir to Three Generic Drug Companies in Sub-Saharan Africa

...Roche on Friday said it will provide three generic drug companies in sub-Saharan Africa assistance in producing the protease inhibitor saquinavir under its Technology Transfer Initiative (TTI)...The technology transfer for saquinavir - which is recommended by the World Health Organization as a second-line HIV/AIDS treatment in resource-poor countries - is available to drug makers in 63 developing nations...Roche will transfer the technology to South Africa-based Aspen Pharmacare and Kenya-based Cosmos and Universal Corp...Another 25 companies have expressed interest in the TTI.